Stay current on changes and developments in corporate law with a wide variety of resources and tools.
July 16 -- A shareholder of drugmaker CytRx Corp. is suing company directors and officers for issuing stock options immediately ahead of a major announcement concerning clinic trials.
Plaintiff shareholder David Johnson filed the derivative complaint July 15 in the Delaware Court of Chancery claiming that officers and directors breached their fiduciary duties of good faith and loyalty, causing unjust enrichment and waste of corporate assets.
According to the complaint, the board's compensation committee approved “spring-loaded” stock options for the company's directors and a handful of top executives, including President and Chief Executive Officer Steven A. Kriegsman, on Dec. 10, 2013. The approval came one day before the company announced to the public “highly positive top-line efficacy results” from a clinic trial of a new chemotherapeutic agent.
On Dec. 11, 2013, CytRx's stock price opened at $3.90, an increase of 63 percent from the previous day's closing price of $2.39, the complaint states. By the close of trading Dec. 11, 2013, the price closed at $4.02, which represents a full-day increase of 68 percent.
The stock price rose to a two-year high of $6.12 by Dec. 12, 2013, the complaint states.
According to the complaint, Kriegsman characterized the Dec. 10 announcement of the clinical trial results as “clearly the most important news in our Company's history,” during a conference call with investors and analysts.
Calls to Los Angeles-based CytRx for comment July 16 were not immediately returned.
During the company's June 24 annual shareholders meeting, Kriegsman and Marvin Selter were reelected to serve another term on the company's staggered board, according to an 8-K filing with the Securities and Exchange Commission.
Also, approximately 77 percent of the shares cast voted in favor on the company's compensation package for certain named officers, including Kriegsman.
The complaint is available at http://www.bloomberglaw.com/public/document/Johnson_David_vs_Louis_Ignarro_Docket_No_9884_Del_Ch_July_15_2014.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)